Cardiff Oncology Reports 2025 Financial Results and Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CRDF?
Source: NASDAQ.COM
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDF
Wall Street analysts forecast CRDF stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.940
Low
10.00
Averages
13.67
High
19.00
Current: 1.940
Low
10.00
Averages
13.67
High
19.00
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations
- Executive Departures: Cardiff Oncology's CEO Mark Erlander and CFO James Levine resigned, causing shares to plummet approximately 35% to a new 52-week low, indicating market concerns over leadership instability.
- Interim Leadership: The board appointed veteran biotech executive Mani Mohindru as interim CEO to replace Erlander, ensuring operational continuity during the executive transition period.
- Financial Stability: Brigitte Lindsay was promoted to Chief Accounting Officer to maintain the finance department's functionality, reflecting the company's commitment to financial management amid leadership changes.
- Clinical Trial Update: Cardiff announced plans to further test a 30 mg dose of its lead drug onvansertib in combination with FOLFIRI/bevacizumab, with a registrational trial expected to begin later this year pending FDA design confirmation, aiming to provide new treatment options for RAS-mutated metastatic colorectal cancer.
See More
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
- Regulatory Milestone: Oncolytics Biotech has secured FDA approval for its pivotal Phase 3 trial design for pelareorep in pancreatic cancer, marking a significant step in a field lacking existing immunotherapy options, potentially providing new treatment avenues for patients.
- Clinical Trial Design: The trial will compare standard chemotherapy with pelareorep, with overall survival as the primary endpoint, and success could solidify Oncolytics' position in a competitive market, enhancing its market standing.
- Market Potential: Analysts project the global immuno-oncology market will grow at a CAGR of 15.7% to reach $416.28 billion by 2034, positioning Oncolytics favorably within this rapidly expanding sector.
- Strategic Development: Oncolytics has also established a Gastrointestinal Scientific Advisory Board to advance pelareorep beyond pancreatic cancer, further expanding its market potential and demonstrating the company's strategic focus on multiple tumor types.
See More
Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025
Clinical Trial Results: Cardiff Oncology presented new data from a Phase 1 trial of onvansertib, a PLK1 inhibitor, for treating relapsed/refractory chronic myelomonocytic leukemia (CMML) at the ASH Annual Meeting, showing preliminary efficacy in about 40% of patients.
Drug Tolerability: Onvansertib was well-tolerated as a monotherapy, with manageable treatment-emergent adverse events reported among the nine enrolled patients.
Future Development Plans: Although Cardiff Oncology does not plan to further develop onvansertib for CMML, the results support its potential in treating various hematologic and solid tumors.
Stock Performance: Following the announcement, Cardiff Oncology's stock rose by 10.90% to $2.34, with a slight increase in after-hours trading, reflecting positive investor sentiment.
See More
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations
- Executive Departures: Cardiff Oncology's CEO Mark Erlander and CFO James Levine resigned, causing shares to plummet approximately 35% to a new 52-week low, indicating market concerns over leadership instability.
- Interim Leadership: The board appointed veteran biotech executive Mani Mohindru as interim CEO to replace Erlander, ensuring operational continuity during the executive transition period.
- Financial Stability: Brigitte Lindsay was promoted to Chief Accounting Officer to maintain the finance department's functionality, reflecting the company's commitment to financial management amid leadership changes.
- Clinical Trial Update: Cardiff announced plans to further test a 30 mg dose of its lead drug onvansertib in combination with FOLFIRI/bevacizumab, with a registrational trial expected to begin later this year pending FDA design confirmation, aiming to provide new treatment options for RAS-mutated metastatic colorectal cancer.
See More
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
- Regulatory Milestone: Oncolytics Biotech has secured FDA approval for its pivotal Phase 3 trial design for pelareorep in pancreatic cancer, marking a significant step in a field lacking existing immunotherapy options, potentially providing new treatment avenues for patients.
- Clinical Trial Design: The trial will compare standard chemotherapy with pelareorep, with overall survival as the primary endpoint, and success could solidify Oncolytics' position in a competitive market, enhancing its market standing.
- Market Potential: Analysts project the global immuno-oncology market will grow at a CAGR of 15.7% to reach $416.28 billion by 2034, positioning Oncolytics favorably within this rapidly expanding sector.
- Strategic Development: Oncolytics has also established a Gastrointestinal Scientific Advisory Board to advance pelareorep beyond pancreatic cancer, further expanding its market potential and demonstrating the company's strategic focus on multiple tumor types.
See More
Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025
Clinical Trial Results: Cardiff Oncology presented new data from a Phase 1 trial of onvansertib, a PLK1 inhibitor, for treating relapsed/refractory chronic myelomonocytic leukemia (CMML) at the ASH Annual Meeting, showing preliminary efficacy in about 40% of patients.
Drug Tolerability: Onvansertib was well-tolerated as a monotherapy, with manageable treatment-emergent adverse events reported among the nine enrolled patients.
Future Development Plans: Although Cardiff Oncology does not plan to further develop onvansertib for CMML, the results support its potential in treating various hematologic and solid tumors.
Stock Performance: Following the announcement, Cardiff Oncology's stock rose by 10.90% to $2.34, with a slight increase in after-hours trading, reflecting positive investor sentiment.
See More
